Biological markers of melancholia and reclassification of depressive disorders.
Pathophysiological markers of melancholia are being developed in four major areas: 1) neuroendocrine; 2) sleep; 3) psychomotor and 4) biochemical. Neuroendocrine markers include a failure of suppress plasma cortisol secretion in the dexamethasone suppression test (DST), diminished thyrotrophin (TSH) response to thyrotrophin releasing hormone (TRH stimulation test), and blunted growth hormone response to a variety of stimulating agents such as d-amphetamine, methylamphetamine, clonidine, L-dopa and insulin (growth hormone test). Of these, the DST is the best standardized. It is a highly specific laboratory marker with documented value in diagnosis, assessing prognosis and monitoring treatment progress. Sleep EEG abnormalities include reduced REM latency, increased REM density, reduction in delta sleep and impaired sleep efficiency. Sleep EEGs are pragmatically difficult, but results are quite specific. Elongated speech pause time (SPT) during "automatic speech" is a promising marker of psychomotor regulation. This simple, non-invasive measure may have special value in reducing clinical subjectivity and in monitoring treatment progress. Biochemical markers include: 1) platelet monoamine oxidase (MAO) activity; 2) in vitro lithium RBC transport and 3) urinary MHPG levels. Standardizations of biochemical tests are still lacking. Most biological tests for melancholia operate by indirectly "marking" CNS limbic system dysfunction. For wide acceptance, a test must be safe, moderately sensitive, highly specific, practical, relatively inexpensive and not significantly altered by common anti-depressant treatments. The DST best meets these criteria at this time. Proper utilization of test results requires knowledge of baseline prevalence rates and of the concepts of sensitivity (true-positive rate), specificity (true negative rate) and positive and negative predictive values (diagnostic confidence). No single marker will meet all clinical needs. Combinations or serial use of tests will hopefully enhance their already considerable usefulness.
D003866:Depressive Disorder / Q000145:classification / Q000175:diagnosis / Q000201:enzymology*; D003907:Dexamethasone; D004569:Electroencephalography; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008094:Lithium / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D008550:Melatonin / Q000097:blood; D008734:Methoxyhydroxyphenylglycol / Q000652:urine; D008995:Monoamine Oxidase / Q000097:blood; D009043:Motor Activity / Q000502:physiology; D011388:Prolactin / Q000097:blood; D012894:Sleep Stages / Q000502:physiology; D013973:Thyrotropin-Releasing Hormone
D008734:Methoxyhydroxyphenylglycol; D013973:Thyrotropin-Releasing Hormone; D003907:Dexamethasone; D011388:Prolactin; D007986:Luteinizing Hormone; D013006:Growth Hormone; D008094:Lithium; D008995:Monoamine Oxidase; D008550:Melatonin; D006854:Hydrocortisone